iaslc Home
Home
Featured Topics
Diagnostic Oncology
Early Detection & Screening
Evolving Standards of Care
Global Initiatives
Meeting News
Names & News
Nursing & Allied Health
Patient Advocacy
Radiation Oncology
Regulatory News
Risk Assessment and Reduction
Society News
Supportive & Palliative Care
Surgical Oncology
Tobacco & Smoking Cessation
WCLC News
Featured Industry Events
ATTENDEE MAP & PHOTOS
Register Now
Menu
Home
Featured Topics
Diagnostic Oncology
Early Detection & Screening
Evolving Standards of Care
Global Initiatives
Meeting News
Names & News
Nursing & Allied Health
Patient Advocacy
Radiation Oncology
Regulatory News
Risk Assessment and Reduction
Society News
Supportive & Palliative Care
Surgical Oncology
Tobacco & Smoking Cessation
WCLC News
Featured Industry Events
ATTENDEE MAP & PHOTOS
Register Now
Home
Evolving Standards of Care
U.S. Drug Approvals: 2010 – 2020
U.S. Drug Approvals: 2010 – 2020
on:
April 16, 2020
In:
Evolving Standards of Care
Print
Email
Share
0
Tweet
Share
Posted:
April 16, 2020
Tags:
afatinib
alectinib
atezolizumab
brigatinib
ceritinib
crizotinib
dabrafenib
dacomitinib
decade in review
durvalumab
erlotinib
gefitinib
larotrectinib
lorlatinib
necitumumab
nivolumab
osimertinib
pembrolizumab
ramucirumab
trametinib
Share
0
Tweet
Share
About the authors
Related Articles
Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients
June 21, 2022
More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors
June 21, 2022
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates
June 07, 2022
Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making
June 07, 2022
Follow IASLC on Twitter
Tweets by @IASLC